![]() ![]() So, be cautious in the near-term, but because the company seems poised for long term growth, I would be a buyer anytime the stock crosses significantly below the 14.50 institutional sale price. Although the stock price has plenty of room to move higher long-term, its near-term movement should hover around the $14.50 institutional sale price. If you happened to buy this stock just last week in the mid-14’s you may want to take some profits and repurchase the stock at a later time. AUXL stock price reacted very favorably to the news on Friday, posting a 7.44% gain up $1.08 to $15.59. The offering is expected to close on or before June 13. Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield. The offer is supposed to net proceeds of about $49.9 million, which will be used for general corporate purposes, including working capital, product development and capital expenditures. ( NASDAQ: AUXL) said it agreed to sell about 3.7 million shares of stock for $14.50 per share to some institutional investors. In all cases, Call option holders exercising in order to obtain stock. It should be noted that AUXL Shares may NOT be delivered pursuant to an election under Notices of Guaranteed Delivery. Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. After the bell on Thursday, specialty biotech drug developer Auxilium Pharmaceuticals Inc. Shares of Auxilium Pharmaceutical (AUXL) are down -15.02 to 23.25 in pre-market trade after the biopharmaceutical company announced that it's reducing its financial guidance for the full year. AUXL Shareholders must observe all terms and conditions for the election as specified in the AUXL proxy statement/prospectus dated December 24, 2014. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |